NeuroPace

NeuroPace is the developer and manufacturer of the RNS System, the first FDA-approved closed-loop responsive neurostimulation device for drug-resistant focal epilepsy. Founded in 1997 and public since 2021 (Nasdaq: NPCE), NeuroPace has treated over 4,000 epilepsy patients. The RNS System implant continuously monitors brain activity and delivers brief electrical pulses to abort seizures before they occur — a landmark in closed-loop BCI for therapeutic applications. Long-term RESPONSE study data shows 75% median seizure reduction over 9 years of use.